Naproxcinod

M01AE18(WHO) 4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate 163133-43-5Y 9884642 8060316N V24GR4LI3I D09568N CHEBI:76254N DTXSID20167523 Interactive image C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OCCCCO[N+](=O)[O-] InChI=1S/C18H21NO6/c1-13(18(20)24-9-3-4-10-25-19(21)22)14-5-6-16-12-17(23-2)8-7-15(16)11-14/h5-8,11-13H,3-4,9-10H2,1-2H3/t13-/m0/s1NKey:AKFJWRDCWYYTIG-ZDUSSCGKSA-NN Naproxcinod(nitronaproxen) is anonsteroidal anti-inflammatory drug(NSAID) developed by the French pharmaceutical companyNicOx. It is aderivativeofnaproxenwith a nitroxybutylesterto allow it to also act as anitric oxide(NO) donor. This secondmechanism of actionmakes naproxcinod the first in a new class of drugs, thecyclooxygenase inhibiting nitric oxide donators(CINODs), that are hoped to produce similaranalgesicefficacy to traditional NSAIDs, but with less gastrointestinal and cardiovascular side effects. In December 2006,Scientific Americandistinguished naproxcinod as one of the ten most promising treatments for the world's biggest health threats.However, in 2010 theU.S. Food and Drug Administrationdetermined that further clinical trials would be needed to obtain approval.